Drug
Tcrt Eso A2
Tcrt Eso A2: highest development phase Phase 1, developed by Athenex. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Athenex
Trials
| Drug | Phase | Indication |
|---|---|---|
| TCRT-ESO-A2 NCT04878484 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Tcrt Eso A2 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.